Cervical Cancer - Pipeline Review, H2 2017

Date: November 30, 2017
Pages: 674
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CE54C688042EN
Leaflet:

Download PDF Leaflet

Cervical Cancer - Pipeline Review, H2 2017
Cervical Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 34, 36, 47, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 4, 11 and 6 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Cervical Cancer - Overview
Cervical Cancer - Therapeutics Development
Cervical Cancer - Therapeutics Assessment
Cervical Cancer - Companies Involved in Therapeutics Development
Cervical Cancer - Drug Profiles
Cervical Cancer - Dormant Projects
Cervical Cancer - Discontinued Products
Cervical Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Cervical Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cervical Cancer - Pipeline by Abion Inc, H2 2017
Cervical Cancer - Pipeline by Abivax SA, H2 2017
Cervical Cancer - Pipeline by Admedus Ltd, H2 2017
Cervical Cancer - Pipeline by Advaxis Inc, H2 2017
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Cervical Cancer - Pipeline by Agenus Inc, H2 2017
Cervical Cancer - Pipeline by Amgen Inc, H2 2017
Cervical Cancer - Pipeline by AntiCancer Inc, H2 2017
Cervical Cancer - Pipeline by Antigen Express Inc, H2 2017
Cervical Cancer - Pipeline by Arbor Vita Corp, H2 2017
Cervical Cancer - Pipeline by ArQule Inc, H2 2017
Cervical Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2017
Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Cervical Cancer - Pipeline by Bayer AG, H2 2017
Cervical Cancer - Pipeline by BeiGene Ltd, H2 2017
Cervical Cancer - Pipeline by Bioleaders Corp, H2 2017
Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Cervical Cancer - Pipeline by Blirt SA, H2 2017
Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Cervical Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Cervical Cancer - Pipeline by Cadila Healthcare Ltd, H2 2017
Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2017
Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
Cervical Cancer - Pipeline by Coherus BioSciences Inc, H2 2017
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017
Cervical Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2017
Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
Cervical Cancer - Pipeline by Eisai Co Ltd, H2 2017
Cervical Cancer - Pipeline by Etubics Corp, H2 2017
Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2017
Cervical Cancer - Pipeline by EyeGene Inc, H2 2017
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Cervical Cancer - Pipeline by Formune SL, H2 2017
Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2017
Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017
Cervical Cancer - Pipeline by Genentech Inc, H2 2017
Cervical Cancer - Pipeline by Genmab A/S, H2 2017
Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Cervical Cancer - Pipeline by Glycostem Therapeutics BV, H2 2017
Cervical Cancer - Pipeline by Glycotope GmbH, H2 2017
Cervical Cancer - Pipeline by Gradalis Inc, H2 2017
Cervical Cancer - Pipeline by Immunomedics Inc, H2 2017
Cervical Cancer - Pipeline by Immunovaccine Inc, H2 2017
Cervical Cancer - Pipeline by Innate Pharma SA, H2 2017
Cervical Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Cervical Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017
Cervical Cancer - Pipeline by Johnson & Johnson, H2 2017
Cervical Cancer - Pipeline by Juno Therapeutics Inc, H2 2017
Cervical Cancer - Pipeline by Kaketsuken, H2 2017
Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2017
Cervical Cancer - Pipeline by LondonPharma Ltd, H2 2017
Cervical Cancer - Pipeline by Mabion SA, H2 2017
Cervical Cancer - Pipeline by MedImmune LLC, H2 2017
Cervical Cancer - Pipeline by Merck & Co Inc, H2 2017
Cervical Cancer - Pipeline by Merck KGaA, H2 2017
Cervical Cancer - Pipeline by Mycenax Biotech Inc, H2 2017
Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2017
Cervical Cancer - Pipeline by NeoImmuneTech Inc, H2 2017
Cervical Cancer - Pipeline by Ology Bioservices Inc, H2 2017
Cervical Cancer - Pipeline by Oncobiologics Inc, H2 2017
Cervical Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017
Cervical Cancer - Pipeline by PDS Biotechnology Corp, H2 2017
Cervical Cancer - Pipeline by Pfizer Inc, H2 2017
Cervical Cancer - Pipeline by Pharma Mar SA, H2 2017
Cervical Cancer - Pipeline by Psicofarma SA de CV, H2 2017
Cervical Cancer - Pipeline by Puma Biotechnology Inc, H2 2017
Cervical Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017
Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H2 2017
Cervical Cancer - Pipeline by Samyang Holdings Corp, H2 2017
Cervical Cancer - Pipeline by Sanofi, H2 2017
Cervical Cancer - Pipeline by Seattle Genetics Inc, H2 2017
Cervical Cancer - Pipeline by Selecta Biosciences Inc, H2 2017
Cervical Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017
Cervical Cancer - Pipeline by Sirnaomics Inc, H2 2017
Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017
Cervical Cancer - Pipeline by Theralase Technologies Inc, H2 2017
Cervical Cancer - Pipeline by Theravectys SA, H2 2017
Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017
Cervical Cancer - Pipeline by UbiVac LLC, H2 2017
Cervical Cancer - Pipeline by Vectorite Biomedica Inc, H2 2017
Cervical Cancer - Pipeline by VLPbio, H2 2017
Cervical Cancer - Pipeline by Wellstat Biologics Corp, H2 2017
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017
Cervical Cancer - Dormant Projects, H2 2017
Cervical Cancer - Dormant Projects, H2 2017 (Contd.1), H2 2017
Cervical Cancer - Dormant Projects, H2 2017 (Contd.2), H2 2017
Cervical Cancer - Dormant Projects, H2 2017 (Contd.3), H2 2017
Cervical Cancer - Dormant Projects, H2 2017 (Contd.4), H2 2017
Cervical Cancer - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Cervical Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Abion Inc
Abivax SA
Admedus Ltd
Advaxis Inc
Advenchen Laboratories LLC
Agenus Inc
Amgen Inc
AntiCancer Inc
Antigen Express Inc
Arbor Vita Corp
ArQule Inc
Asana BioSciences LLC
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Bioleaders Corp
Biomics Biotechnologies Co Ltd
Blirt SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cancer Research Technology Ltd
Celleron Therapeutics Ltd
Coherus BioSciences Inc
Critical Outcome Technologies Inc
Cytori Therapeutics Inc
CZ BioMed Corp
DelMar Pharmaceuticals Inc
Dr. Reddy's Laboratories Ltd
Eisai Co Ltd
Etubics Corp
Eureka Therapeutics Inc
EyeGene Inc
F. Hoffmann-La Roche Ltd
Formune SL
GamaMabs Pharma SA
Gene Techno Science Co Ltd
Genentech Inc
Genmab A/S
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Glycostem Therapeutics BV
Glycotope GmbH
Gradalis Inc
Immunomedics Inc
Immunovaccine Inc
Innate Pharma SA
Innovation Pharmaceuticals Inc
Iovance Biotherapeutics Inc
ISA Pharmaceuticals BV
Johnson & Johnson
Juno Therapeutics Inc
Kaketsuken
Karyopharm Therapeutics Inc
Kite Pharma Inc
LondonPharma Ltd
Mabion SA
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mycenax Biotech Inc
Nektar Therapeutics
NeoImmuneTech Inc
Ology Bioservices Inc
Oncobiologics Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
Psicofarma SA de CV
Puma Biotechnology Inc
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Richter Gedeon Nyrt
Samyang Holdings Corp
Sanofi
Seattle Genetics Inc
Selecta Biosciences Inc
Shantha Biotechnics Pvt Ltd
Sirnaomics Inc
Sun Pharma Advanced Research Company Ltd
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Theravectys SA
THEVAX Genetics Vaccine USA Inc
UbiVac LLC
Vectorite Biomedica Inc
VLPbio
Wellstat Biologics Corp
Zeria Pharmaceutical Co Ltd
Skip to top


Ask Your Question

Cervical Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: